Anushka Patel1, Devarsetty Praveen2, Asri Maharani3, Delvac Oceandy4,5, Quentin Pilard1, Mohan P S Kohli6, Sujarwoto Sujarwoto7, Gindo Tampubolon8. 1. The George Institute for Global Health, University of New South Wales, Sydney, Australia. 2. The George Institute for Global Health, University of New South Wales, Hyderabad, India. 3. Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom. 4. Division of Cardiovascular Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom. 5. Department of Biomedicine, Faculty of Medicine, University of Airlangga, Surabaya, Indonesia. 6. Independent Public Health Consultant, New Delhi, India. 7. Department of Public Administration, University of Brawijaya, Malang, Indonesia. 8. Global Development Institute, The University of Manchester, Manchester, United Kingdom.
Abstract
Importance: Cardiovascular diseases (CVDs) are the leading cause of disease burden in Indonesia. Implementation of effective interventions for CVD prevention is limited. Objective: To evaluate whether a mobile technology-supported primary health care intervention, compared with usual care, would improve the use of preventive drug treatment among people in rural Indonesia with a high risk of CVD. Design, Setting, and Participants: A quasi-experimental study involving 6579 high-risk individuals in 4 intervention and 4 control villages in Malang district, Indonesia, was conducted between August 16, 2016, and March 31, 2018. Median duration of follow-up was 12.2 months. Residents 40 years or older were invited to participate. Those with high estimated 10-year risk of CVD risk (previously diagnosed CVD, systolic blood pressure [BP] >160 mm Hg or diastolic BP >100 mm Hg, 10-year estimated CVD risk of 30% or more, or 10-year estimated CVD risk of 20%-29% and a systolic BP >140 mm Hg) were followed up. Interventions: A multifaceted mobile technology-supported intervention facilitating community-based CVD risk screening with referral, tailored clinical decision support for drug prescription, and patient follow-up. Main Outcomes and Measures: The primary outcome was the proportion of individuals taking appropriate preventive CVD medications, defined as at least 1 BP-lowering drug and a statin for all high-risk individuals, and an antiplatelet drug for those with prior diagnosed CVD. Secondary outcomes included mean change in BP from baseline. Results: Among 22 635 adults, 3494 of 11 647 in the intervention villages (30.0%; 2166 women and 1328 men; mean [SD] age, 58.3 [10.9] years) and 3085 of 10 988 in the control villages (28.1%; 1838 women and 1247 men; mean [SD] age, 59.0 [11.5] years) had high estimated risk of CVD. Of these, follow-up was completed in 2632 individuals (75.3%) from intervention villages and 2429 individuals (78.7%) from control villages. At follow-up, 409 high-risk individuals in intervention villages (15.5%) were taking appropriate preventive CVD medications, compared with 25 (1.0%) in control villages (adjusted risk difference, 14.1%; 95% CI, 12.7%-15.6%). This difference was driven by higher use of BP-lowering medication in those in the intervention villages (1495 [56.8%] vs 382 [15.7%]; adjusted risk difference, 39.4%; 95% CI, 37.0%-41.7%). The adjusted mean difference in change in systolic BP from baseline was -8.3 mm Hg (95% CI, -10.1 to -6.6 mm Hg). Conclusions and Relevance: This study found that a multifaceted mobile technology-supported primary health care intervention was associated with greater use of preventive CVD medication and lower BP levels among high-risk individuals in a rural Indonesian population.
Importance: Cardiovascular diseases (CVDs) are the leading cause of disease burden in Indonesia. Implementation of effective interventions for CVD prevention is limited. Objective: To evaluate whether a mobile technology-supported primary health care intervention, compared with usual care, would improve the use of preventive drug treatment among people in rural Indonesia with a high risk of CVD. Design, Setting, and Participants: A quasi-experimental study involving 6579 high-risk individuals in 4 intervention and 4 control villages in Malang district, Indonesia, was conducted between August 16, 2016, and March 31, 2018. Median duration of follow-up was 12.2 months. Residents 40 years or older were invited to participate. Those with high estimated 10-year risk of CVD risk (previously diagnosed CVD, systolic blood pressure [BP] >160 mm Hg or diastolic BP >100 mm Hg, 10-year estimated CVD risk of 30% or more, or 10-year estimated CVD risk of 20%-29% and a systolic BP >140 mm Hg) were followed up. Interventions: A multifaceted mobile technology-supported intervention facilitating community-based CVD risk screening with referral, tailored clinical decision support for drug prescription, and patient follow-up. Main Outcomes and Measures: The primary outcome was the proportion of individuals taking appropriate preventive CVD medications, defined as at least 1 BP-lowering drug and a statin for all high-risk individuals, and an antiplatelet drug for those with prior diagnosed CVD. Secondary outcomes included mean change in BP from baseline. Results: Among 22 635 adults, 3494 of 11 647 in the intervention villages (30.0%; 2166 women and 1328 men; mean [SD] age, 58.3 [10.9] years) and 3085 of 10 988 in the control villages (28.1%; 1838 women and 1247 men; mean [SD] age, 59.0 [11.5] years) had high estimated risk of CVD. Of these, follow-up was completed in 2632 individuals (75.3%) from intervention villages and 2429 individuals (78.7%) from control villages. At follow-up, 409 high-risk individuals in intervention villages (15.5%) were taking appropriate preventive CVD medications, compared with 25 (1.0%) in control villages (adjusted risk difference, 14.1%; 95% CI, 12.7%-15.6%). This difference was driven by higher use of BP-lowering medication in those in the intervention villages (1495 [56.8%] vs 382 [15.7%]; adjusted risk difference, 39.4%; 95% CI, 37.0%-41.7%). The adjusted mean difference in change in systolic BP from baseline was -8.3 mm Hg (95% CI, -10.1 to -6.6 mm Hg). Conclusions and Relevance: This study found that a multifaceted mobile technology-supported primary health care intervention was associated with greater use of preventive CVD medication and lower BP levels among high-risk individuals in a rural Indonesian population.
Authors: S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil Journal: J Clin Epidemiol Date: 2001-04 Impact factor: 6.437
Authors: Rohina Joshi; Mohammed Alim; Andre Pascal Kengne; Stephen Jan; Pallab K Maulik; David Peiris; Anushka A Patel Journal: PLoS One Date: 2014-08-14 Impact factor: 3.240
Authors: Nafsiah Mboi; Indra Murty Surbakti; Indang Trihandini; Iqbal Elyazar; Karen Houston Smith; Pungkas Bahjuri Ali; Soewarta Kosen; Kristin Flemons; Sarah E Ray; Jackie Cao; Scott D Glenn; Molly K Miller-Petrie; Meghan D Mooney; Jeffrey L Ried; Dina Nur Anggraini Ningrum; Fachmi Idris; Kemal N Siregar; Pandu Harimurti; Robert S Bernstein; Tikki Pangestu; Yuwono Sidharta; Mohsen Naghavi; Christopher J L Murray; Simon I Hay Journal: Lancet Date: 2018-06-28 Impact factor: 79.321
Authors: Nina T Castillo-Carandang; Robert D Buenaventura; Yook-Chin Chia; Dung Do Van; Cheng Lee; Ngoc Long Duong; Chee H Ng; Yolanda R Robles; Anwar Santoso; Helen S Sigua; Apichard Sukonthasarn; Roger Tan; Eka Viora; Hazli Zakaria; Grace E Brizuela; Priyan Ratnasingham; Mathew Thomas; Anurita Majumdar Journal: Risk Manag Healthc Policy Date: 2020-07-15
Authors: LaPrincess C Brewer; Karen L Fortuna; Clarence Jones; Robert Walker; Sharonne N Hayes; Christi A Patten; Lisa A Cooper Journal: JMIR Mhealth Uhealth Date: 2020-01-14 Impact factor: 4.773
Authors: Shobhana Nagraj; Stephen H Kennedy; Robyn Norton; Vivekananda Jha; Devarsetty Praveen; Lisa Hinton; Jane E Hirst Journal: Front Cardiovasc Med Date: 2020-03-20
Authors: Ikechi G Okpechi; Shezel Muneer; Feng Ye; Deenaz Zaidi; Anukul Ghimire; Mohammed M Tinwala; Syed Saad; Mohamed A Osman; Joseph Lunyera; Marcello Tonelli; Fergus Caskey; Cindy George; Andre P Kengne; Charu Malik; Sandrine Damster; Adeera Levin; David Johnson; Vivekanand Jha; Aminu K Bello Journal: BMJ Open Date: 2022-03-23 Impact factor: 2.692